Literature DB >> 26977579

Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come.

Naveena Singh1, C Blake Gilks, Lynn Hirshowitz, Nafisa Wilkinson, W Glenn McCluggage.   

Abstract

There is currently sufficient evidence that nonuterine high-grade serous carcinoma (HGSC) originates in the fallopian tube in the majority of cases, but this is not uniformly reflected in our diagnostic terminology. This is because there remains wide variation in awareness and acceptance of this evidence, which conflicts with traditional views on origin. Accurate disease classification is fundamental to routine clinical practice and research, particularly at a time when exciting new approaches to therapy, early detection, and prevention are appearing on the horizon. We feel the time has come to minimize individual and institutional variations in practice, and agree on an evidence-based approach to uniform terminology and primary site assignment. In this paper we put forward a proposal for a unified approach based on published research evidence and discuss the reasons why it is vital to agree on a uniform protocol. We propose the term "Tubo-ovarian HGSC" in preference to "pelvic" or "Müllerian," as it accurately reflects the origin of this disease in the vast majority of cases, and is unambiguous, distinguishing it clearly from uterine serous carcinoma and ovarian low-grade serous carcinomas. A detailed protocol for primary site assignment is presented for different scenarios, which is easy to follow and has been developed with a view to promoting a uniform approach worldwide.

Entities:  

Mesh:

Year:  2016        PMID: 26977579     DOI: 10.1097/PGP.0000000000000270

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

Review 2.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Authors:  Naveena Singh; Asma Faruqi; Friedrich Kommoss; W Glenn McCluggage; Giorgia Trevisan; Janine Senz; Amy Lum; C Blake Gilks; Michael Anglesio
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

Review 4.  Progress in the pathological arena of gynecological cancers.

Authors:  W Glenn McCluggage
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

5.  Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  James Dilley; Matthew Burnell; Aleksandra Gentry-Maharaj; Andy Ryan; Christina Neophytou; Sophia Apostolidou; Chloe Karpinskyj; Jatinderpal Kalsi; Tim Mould; Robert Woolas; Naveena Singh; Martin Widschwendter; Lesley Fallowfield; Stuart Campbell; Steven J Skates; Alistair McGuire; Mahesh Parmar; Ian Jacobs; Usha Menon
Journal:  Gynecol Oncol       Date:  2020-06-17       Impact factor: 5.482

Review 6.  Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.

Authors:  Laura Feeney; Ian Jg Harley; W Glenn McCluggage; Paul B Mullan; James P Beirne
Journal:  World J Clin Oncol       Date:  2020-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.